



## Clinical trial results:

### An Open-label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-positive Cancers

#### Summary

EudraCT number	2011-004426-10
Trial protocol	GB ES DE
Global end of trial date	27 October 2016

#### Results information

Result version number	v2 (current)
This version publication date	04 November 2017
First version publication date	07 September 2017
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	MO28072
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01524978
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 October 2016
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	27 October 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study is to assess the efficacy of vemurafenib in subjects with BRAF V600 mutation-positive cancers (solid tumors and multiple myeloma, except melanoma and papillary thyroid cancer) and for whom vemurafenib is deemed the best treatment option in the opinion of the investigator.

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 April 2012
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy, Safety
Long term follow-up duration	1 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 103
Country: Number of subjects enrolled	France: 63
Country: Number of subjects enrolled	Spain: 24
Country: Number of subjects enrolled	Germany: 13
Country: Number of subjects enrolled	United Kingdom: 5
Worldwide total number of subjects	208
EEA total number of subjects	105

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	134
From 65 to 84 years	71
85 years and over	3

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

One participant with breast cancer was screened shortly after Cohort 5 (Breast Cancer) had been closed. This participant was allowed to enter the study in Cohort 7: Other BRAF V600-positive tumors. For analysis purposes Cohort 7 was split into sub-cohorts for indications with sufficient participants.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib

Arm description:

Subjects with NSCLC were treated with vemurafenib monotherapy.

Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

960 milligrams (mg) vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

<b>Arm title</b>	Cohort 2: Ovarian Cancer - vemurafenib
------------------	--

Arm description:

Subjects with ovarian cancer were treated with vemurafenib monotherapy.

Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

960 milligrams (mg) vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

<b>Arm title</b>	Cohort 3a: Colorectal Cancer - vemurafenib
------------------	--

Arm description:

Subjects with colorectal cancer were treated with vemurafenib monotherapy.

Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

960 milligrams (mg) vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

<b>Arm title</b>	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Arm description: Subjects with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.	
Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

Escalating doses were given orally twice a day starting on Day 2 of Cycle 1. The escalating doses were as follows: Dose Level 1: 720 mg of vemurafenib; Dose Level 2: 720 mg of vemurafenib; Dose Level 3: 960 mg of vemurafenib.

Investigational medicinal product name	cetuximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Escalating doses were administered on Day 1 and then once weekly by intravenous infusion. The escalating doses were as follows: Dose Level 1: 300 milligrams per square meter (mg/m<sup>2</sup>) loading dose of cetuximab and then 200 mg/m<sup>2</sup> weekly; Dose Level 2: 400 mg/m<sup>2</sup> loading dose of cetuximab and then 250 mg/m<sup>2</sup> weekly; Dose Level 3: 400 mg/m<sup>2</sup> loading dose of cetuximab and then 250 mg/m<sup>2</sup> weekly.

<b>Arm title</b>	Cohort 4: Cholangiocarcinoma - vemurafenib
Arm description: Subjects with cholangiocarcinoma were treated with vemurafenib monotherapy.	
Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

960 milligrams (mg) vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

<b>Arm title</b>	Cohort 6: Multiple Myeloma - vemurafenib
Arm description: Subjects with multiple myeloma were treated with vemurafenib monotherapy.	
Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

960 milligrams (mg) vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

<b>Arm title</b>	Cohort 7a: ECD/LCH - vemurafenib
Arm description: Subjects with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.	
Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 960 milligrams (mg) vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.	
<b>Arm title</b>	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Arm description: Subjects with anaplastic thyroid cancer were treated with vemurafenib monotherapy.	
Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 960 milligrams (mg) vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.	
<b>Arm title</b>	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib
Arm description: Subjects with advanced stage astrocytoma were treated with vemurafenib monotherapy.	
Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 960 milligrams (mg) vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.	
<b>Arm title</b>	Cohort 7d: Early Stage Astrocytoma - vemurafenib
Arm description: Subjects with early stage astrocytoma were treated with vemurafenib monotherapy.	
Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 960 milligrams (mg) vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.	
<b>Arm title</b>	Other BRAF V600-positive Tumors - vemurafenib
Arm description: Subjects with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.	

Arm type	Experimental
Investigational medicinal product name	vemurafenib
Investigational medicinal product code	
Other name	Zelboraf
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

960 milligrams (mg) vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.

Number of subjects in period 1	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib
Started	62	4	10
Completed	0	0	0
Not completed	62	4	10
Adverse event, serious fatal	34	2	5
Consent withdrawn by subject	12	-	1
Unspecified	16	2	1
Lost to follow-up	-	-	3

Number of subjects in period 1	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib
Started	27	9	9
Completed	0	0	0
Not completed	27	9	9
Adverse event, serious fatal	24	4	4
Consent withdrawn by subject	1	3	1
Unspecified	2	1	3
Lost to follow-up	-	1	1

Number of subjects in period 1	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib
Started	26	12	12
Completed	0	0	0
Not completed	26	12	12
Adverse event, serious fatal	1	9	5
Consent withdrawn by subject	6	2	4
Unspecified	17	1	2
Lost to follow-up	2	-	1

Number of subjects in period 1	Cohort 7d: Early Stage Astrocytoma -	Other BRAF V600-positive Tumors -

	vemurafenib	vemurafenib
Started	9	28
Completed	0	0
Not completed	9	28
Adverse event, serious fatal	6	17
Consent withdrawn by subject	-	5
Unspecified	2	5
Lost to follow-up	1	1



## Baseline characteristics

### Reporting groups

Reporting group title	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib
Reporting group description:	
Subjects with NSCLC were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 2: Ovarian Cancer - vemurafenib
Reporting group description:	
Subjects with ovarian cancer were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 3a: Colorectal Cancer - vemurafenib
Reporting group description:	
Subjects with colorectal cancer were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Reporting group description:	
Subjects with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.	
Reporting group title	Cohort 4: Cholangiocarcinoma - vemurafenib
Reporting group description:	
Subjects with cholangiocarcinoma were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 6: Multiple Myeloma - vemurafenib
Reporting group description:	
Subjects with multiple myeloma were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 7a: ECD/LCH - vemurafenib
Reporting group description:	
Subjects with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Reporting group description:	
Subjects with anaplastic thyroid cancer were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib
Reporting group description:	
Subjects with advanced stage astrocytoma were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 7d: Early Stage Astrocytoma - vemurafenib
Reporting group description:	
Subjects with early stage astrocytoma were treated with vemurafenib monotherapy.	
Reporting group title	Other BRAF V600-positive Tumors - vemurafenib
Reporting group description:	
Subjects with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.	

Reporting group values	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib
Number of subjects	62	4	10
Age categorical			
Units: Subjects			
Adults (18-64 years)	30	4	10
From 65-84 years	30	0	0
85 years and over	2	0	0

Age Continuous Units: years arithmetic mean standard deviation	65.4 ± 10.2	45.8 ± 5.3	57.3 ± 5.4
Gender, Male/Female Units: Subjects			
Female	27	4	5
Male	35	0	5

<b>Reporting group values</b>	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib
Number of subjects	27	9	9
Age categorical Units: Subjects			
Adults (18-64 years)	15	8	7
From 65-84 years	12	1	2
85 years and over	0	0	0
Age Continuous Units: years arithmetic mean standard deviation	64.3 ± 8.8	53.2 ± 9.7	62.1 ± 4.3
Gender, Male/Female Units: Subjects			
Female	18	5	3
Male	9	4	6

<b>Reporting group values</b>	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib
Number of subjects	26	12	12
Age categorical Units: Subjects			
Adults (18-64 years)	15	6	12
From 65-84 years	11	6	0
85 years and over	0	0	0
Age Continuous Units: years arithmetic mean standard deviation	60.8 ± 13.3	66.8 ± 9.2	41.6 ± 12.2
Gender, Male/Female Units: Subjects			
Female	14	3	8
Male	12	9	4

<b>Reporting group values</b>	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600- positive Tumors - vemurafenib	Total
Number of subjects	9	28	208
Age categorical Units: Subjects			
Adults (18-64 years)	8	19	134

From 65-84 years	1	8	71
85 years and over	0	1	3

Age Continuous			
Units: years			
arithmetic mean	34.3	53.7	
standard deviation	± 20.7	± 17.5	-
Gender, Male/Female			
Units: Subjects			
Female	9	15	111
Male	0	13	97

## End points

### End points reporting groups

Reporting group title	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib
Reporting group description: Subjects with NSCLC were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 2: Ovarian Cancer - vemurafenib
Reporting group description: Subjects with ovarian cancer were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 3a: Colorectal Cancer - vemurafenib
Reporting group description: Subjects with colorectal cancer were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Reporting group description: Subjects with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.	
Reporting group title	Cohort 4: Cholangiocarcinoma - vemurafenib
Reporting group description: Subjects with cholangiocarcinoma were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 6: Multiple Myeloma - vemurafenib
Reporting group description: Subjects with multiple myeloma were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 7a: ECD/LCH - vemurafenib
Reporting group description: Subjects with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Reporting group description: Subjects with anaplastic thyroid cancer were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib
Reporting group description: Subjects with advanced stage astrocytoma were treated with vemurafenib monotherapy.	
Reporting group title	Cohort 7d: Early Stage Astrocytoma - vemurafenib
Reporting group description: Subjects with early stage astrocytoma were treated with vemurafenib monotherapy.	
Reporting group title	Other BRAF V600-positive Tumors - vemurafenib
Reporting group description: Subjects with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.	

### Primary: Confirmed Best Overall Response Rate (BORR)

End point title	Confirmed Best Overall Response Rate (BORR) <sup>[1]</sup>
End point description: Confirmed BORR: percentage of subjects with an objective response (OR) (complete response [CR], partial response [PR], stringent CR [sCR] or very good PR [VGPR]) on 2 occasions $\geq$ 4 weeks apart as assessed by the Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. or International Myeloma Working Group (IMWG) criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: $\geq$ 30% decrease in the sum of diameters of target lesions. IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and $\leq$ 5% plasma cells in bone marrow; PR: $\geq$ 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by $\geq$ 90% or to $<$ 200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or $\geq$ 90% reduction in serum M-protein plus urine M-protein level $<$ 100 mg per 24 hour; sCR: CR plus normal free light chain (FLC) ratio and no	

clonal cells in bone marrow.

End point type	Primary
End point timeframe:	
Up to approximately 3 years	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Primary efficacy results were summarized by cohort each representing specific cancer types. No statistical analyses were done, since all cohorts received vemurafenib treatment.

<b>End point values</b>	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62 <sup>[2]</sup>	4	10	27
Units: percentage of subjects				
number (confidence interval 95%)	37.1 (25.16 to 50.31)	50.0 (6.76 to 93.24)	0 (0.00 to 30.85)	7.4 (0.91 to 24.29)

Notes:

[2] - Intent-to-Treat (ITT) population included all subjects enrolled in the study.

<b>End point values</b>	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	26	12
Units: percentage of subjects				
number (confidence interval 95%)	22.2 (2.81 to 60.01)	22.2 (2.81 to 60.01)	61.5 (40.57 to 79.77)	25.0 (5.49 to 57.19)

<b>End point values</b>	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	9	28	
Units: percentage of subjects				
number (confidence interval 95%)	16.7 (2.09 to 48.41)	33.3 (7.49 to 70.07)	17.9 (6.06 to 36.89)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects with Confirmed Clinical Benefit

End point title	Percentage of Subjects with Confirmed Clinical Benefit
-----------------	--

# End point description:

Confirmed clinical benefit rate: percentage of subjects with confirmed PR or CR or Stable Disease (SD) that have lasted at least 6 months according to RECIST v1.1 or confirmed CR, PR, VGPR, sCR or SD for at least 6 months according to IMWG criteria. RECIST v1.1: PR:  $\geq 30\%$  decrease in the sum of diameters of target lesions; CR: disappearance of all target lesions; SD: not meeting criteria for CR, PR or progressive disease (PD). IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and  $\leq 5\%$  plasma cells in bone marrow; PR:  $\geq 50\%$  reduction of serum M-protein and reduction in 24-hour urinary M-protein by  $\geq 90\%$  or to  $<200$  mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or  $\geq 90\%$  reduction in serum M-protein plus urine M-protein level  $< 100$  mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow; SD: not meeting criteria for CR, VGPR, PR or PD.

End point type	Secondary
End point timeframe:	
Up to approximately 3 years	

End point values	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62 <sup>[3]</sup>	4	10	27
Units: percentage of subjects				
number (confidence interval 95%)	48.4 (35.50 to 61.44)	50.0 (6.76 to 93.24)	0 (-9999 to 9999)	18.5 (6.30 to 38.08)

Notes:

[3] - ITT population: all subjects enrolled. (-)9999 = not estimable due to insufficient number of events

End point values	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	26	12
Units: percentage of subjects				
number (confidence interval 95%)	44.4 (13.70 to 78.80)	22.2 (2.81 to 60.01)	76.9 (56.35 to 91.03)	25.0 (5.49 to 57.19)

End point values	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	9	28	
Units: percentage of subjects				
number (confidence interval 95%)	33.3 (9.92 to 65.11)	44.4 (13.70 to 78.80)	17.9 (6.06 to 36.89)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Response Rate (ORR)

End point title	Overall Response Rate (ORR)
End point description:	
<p>ORR: percentage of subjects with an objective response (OR) (CR, PR, sCR or VGPR) on 2 occasions <math>\geq</math> 4 weeks apart as assessed by the Investigator using RECIST v1.1. or IMWG criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: <math>\geq</math> 30% decrease in the sum of diameters of target lesions. IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and <math>\leq</math> 5% plasma cells in bone marrow; PR: <math>\geq</math> 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by <math>\geq</math> 90% or to <math>&lt;</math>200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or <math>\geq</math> 90% reduction in serum M-protein plus urine M-protein level <math>&lt;</math> 100 mg per 24 hour; sCR: CR plus normal free light chain (FLC) ratio and no clonal cells in bone marrow. ITT population: all subjects enrolled in the study.</p>	
End point type	Secondary
End point timeframe:	
Up to approximately 3 years	

End point values	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62 <sup>[4]</sup>	4	10	27
Units: percentage of subjects				
number (confidence interval 95%)				
CR	0 (0.00 to 5.78)	0 (0.00 to 60.24)	0 (0.00 to 30.85)	0 (0.00 to 12.77)
PR	37.1 (25.16 to 50.31)	50.0 (6.76 to 93.24)	0 (0.00 to 30.85)	7.4 (0.91 to 24.29)
VGPR	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)
sCR	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)

Notes:

[4] - 9999 = not evaluated (only in Cohort 6)

End point values	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	26	12
Units: percentage of subjects				
number (confidence interval 95%)				
CR	0 (0.00 to 33.63)	0 (0.00 to 33.63)	7.7 (0.95 to 25.13)	8.3 (0.21 to 38.48)
PR	22.2 (2.81 to 60.01)	11.1 (0.28 to 48.25)	53.8 (33.37 to 73.41)	16.7 (2.09 to 48.41)
VGPR	9999 (9999 to 9999)	11.1 (0.28 to 48.25)	9999 (9999 to 9999)	9999 (9999 to 9999)

sCR	9999 (9999 to 9999)	0 (0.00 to 33.63)	9999 (9999 to 9999)	9999 (9999 to 9999)
-----	---------------------	-------------------	---------------------	---------------------

End point values	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	9	28	
Units: percentage of subjects				
number (confidence interval 95%)				
CR	8.3 (0.21 to 38.48)	0 (0.00 to 33.63)	3.6 (0.09 to 18.35)	
PR	8.3 (0.21 to 38.48)	33.3 (7.49 to 70.07)	14.3 (4.03 to 32.67)	
VGPR	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	
sCR	9999 (9999 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Response (DOR)

End point title	Duration of Response (DOR)
-----------------	----------------------------

End point description:

DOR was defined as the period from the date of initial PR or CR for solid tumors according to RECISTv1.1 and CR, PR, VGPR or sCR for multiple myeloma according to IMWG criteria, until the date of PD or death from any cause. RECIST v1.1: PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG: PD: increase of  $\geq 25\%$  from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas. ITT population included all subjects enrolled in the study irrespective of whether they had received study medication or not. 9999 = not estimable due to insufficient number of subjects with events.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 3 years

End point values	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	4	10	27
Units: months				
median (confidence interval 95%)	7.16 (5.49 to 18.43)	8.16 (3.88 to 12.45)	9999 (9999 to 9999)	6.54 (5.68 to 7.39)



<b>End point values</b>	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	26	12
Units: months				
median (confidence interval 95%)	12.86 (3.58 to 22.14)	9999 (9999 to 9999)	9999 (9999 to 9999)	9.95 (8.31 to 30.98)

<b>End point values</b>	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	2	9	28	
Units: months				
median (confidence interval 95%)	9999 (13.08 to 9999)	3.42 (2.40 to 7.49)	9.92 (3.48 to 21.22)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Response

End point title	Time to Response
-----------------	------------------

End point description:

Time to response was defined as the time from the first day of study treatment to the date of first CR, or PR for solid tumors according to RECISTv1.1 and CR, PR, VGPR or sCR for multiple myeloma according to IMWG criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: at least a 30% decrease in the sum of diameters of target lesions. IMWG criteria: CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and  $\leq$  5% plasma cells in bone marrow; PR:  $\geq$  50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by  $\geq$  90% or to  $<$  200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or  $\geq$  90% reduction in serum M-protein plus urine M-protein level  $<$  100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow. ITT population: all subjects enrolled in the study. (-)9999 = not estimable due to insufficient number of subjects with events.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 3 years

End point values	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	4	10	27
Units: months				
median (confidence interval 95%)	7.26 (3.68 to 9999)	9999 (1.64 to 9999)	9999 (9999 to 9999)	9999 (9999 to 9999)

End point values	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	26	12
Units: months				
median (confidence interval 95%)	9999 (3.52 to 9999)	5.75 (-9999 to 9999)	5.49 (3.68 to 13.73)	9999 (1.68 to 9999)

End point values	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	9	28	
Units: months				
median (confidence interval 95%)	9999 (1.74 to 9999)	9999 (2.33 to 9999)	9999 (3.68 to 9999)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to Tumor Progression (TTP)

End point title	Time to Tumor Progression (TTP)
-----------------	---------------------------------

End point description:

TTP was defined as time from the first day of study treatment to the first occurrence of progressive disease (PD). RECIST v1.1: PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG: PD: increase of  $\geq 25\%$  from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas. ITT population included all subjects enrolled in the study irrespective of whether they had received study medication or not. 9999 = not estimable due to insufficient number of subjects with events.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 3 years

End point values	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	4	10	27
Units: months				
median (confidence interval 95%)	7.33 (5.29 to 9.66)	6.44 (1.87 to 14.29)	3.88 (1.84 to 5.52)	3.68 (3.45 to 5.39)

End point values	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	26	12
Units: months				
median (confidence interval 95%)	3.02 (1.64 to 9.00)	4.63 (2.89 to 9999)	9999 (9999 to 9999)	2.83 (1.77 to 5.49)

End point values	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	9	28	
Units: months				
median (confidence interval 95%)	5.62 (1.81 to 14.85)	5.36 (3.02 to 9.10)	3.65 (1.68 to 5.75)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Progression free Survival (PFS)

End point title	Progression free Survival (PFS)
-----------------	---------------------------------

End point description:

PFS was defined as the time from the first day of study treatment, until the first documented PD or death from any cause, whichever occurs first. RECIST v1.1: PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG criteria: PD: increase of  $\geq 25\%$  from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas. ITT population included all subjects enrolled in the study irrespective of whether they had received study medication or not. 9999 = not estimable due to insufficient number of subjects with events.

End point type	Secondary
End point timeframe:	
Up to approximately 3 years	

End point values	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	4	10	27
Units: months				
median (confidence interval 95%)	6.51 (5.16 to 8.97)	6.44 (1.87 to 14.29)	3.88 (1.84 to 5.52)	3.68 (1.81 to 5.39)

End point values	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	26	12
Units: months				
median (confidence interval 95%)	3.02 (1.64 to 9.00)	4.63 (2.89 to 9999)	9999 (9999 to 9999)	2.83 (1.77 to 5.49)

End point values	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	9	28	
Units: months				
median (confidence interval 95%)	9.59 (1.81 to 14.78)	5.26 (3.02 to 5.72)	3.12 (1.64 to 5.55)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

OS was defined as time between the first day of study treatment and date of death of any cause. ITT population included all subjects enrolled in the study irrespective of whether they had received study medication or not. 9999 = not estimable due to insufficient number of subjects with events.

End point type	Secondary
End point timeframe:	
Up to approximately 3 years	

End point values	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	4	10	27
Units: months				
median (confidence interval 95%)	15.38 (9.56 to 22.77)	9999 (2.56 to 9999)	9.30 (7.82 to 12.88)	7.16 (5.49 to 11.73)

End point values	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	26	12
Units: months				
median (confidence interval 95%)	17.94 (11.20 to 9999)	24.54 (4.96 to 9999)	9999 (9999 to 9999)	5.88 (2.17 to 16.79)

End point values	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	9	28	
Units: months				
median (confidence interval 95%)	40.11 (9.59 to 40.11)	12.75 (6.70 to 9999)	11.56 (3.71 to 28.16)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum Tolerated Dose for Vemurafenib in Combination with Cetuximab

End point title	Maximum Tolerated Dose for Vemurafenib in Combination with Cetuximab
-----------------	--

End point description:

Cohort 3b included subjects with colorectal cancer treated with escalating doses of vemurafenib and

cetuximab. The escalating doses were as follows: Dose Level 1: 720 milligrams (mg) of vemurafenib orally twice daily starting on Day 2 of Cycle 1 and 300 milligrams per square meter (mg/m<sup>2</sup>) loading dose of cetuximab by infusion and then 200 mg/m<sup>2</sup> weekly; Dose Level 2: 720 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m<sup>2</sup> loading dose of cetuximab and then 250 mg/m<sup>2</sup> weekly; Dose Level 3: 960 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m<sup>2</sup> loading dose of cetuximab and then 250 mg/m<sup>2</sup> weekly. Reported here are the maximum tolerated doses for each vemurafenib and cetuximab. The safety population included all subjects who received at least one dose of study medication.

End point type	Secondary
End point timeframe:	
Up to approximately 3 years	

End point values	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[5]</sup>	0 <sup>[6]</sup>	0 <sup>[7]</sup>	14
Units: milligrams (mg)				
vemurafenib				960
cetuximab				400

Notes:

[5] - Endpoint only applies to combination therapy in cohort 3b.

[6] - Endpoint only applies to combination therapy in cohort 3b.

[7] - Endpoint only applies to combination therapy in cohort 3b.

End point values	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[8]</sup>	0 <sup>[9]</sup>	0 <sup>[10]</sup>	0 <sup>[11]</sup>
Units: milligrams (mg)				
vemurafenib				
cetuximab				

Notes:

[8] - Endpoint only applies to combination therapy in cohort 3b.

[9] - Endpoint only applies to combination therapy in cohort 3b.

[10] - Endpoint only applies to combination therapy in cohort 3b.

[11] - Endpoint only applies to combination therapy in cohort 3b.

End point values	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 <sup>[12]</sup>	0 <sup>[13]</sup>	0 <sup>[14]</sup>	
Units: milligrams (mg)				
vemurafenib				
cetuximab				

Notes:

[12] - Endpoint only applies to combination therapy in cohort 3b.

[13] - Endpoint only applies to combination therapy in cohort 3b.

[14] - Endpoint only applies to combination therapy in cohort 3b.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Dose-limiting Toxicities of Vemurafenib in Combination with Cetuximab

End point title	Number of Dose-limiting Toxicities of Vemurafenib in Combination with Cetuximab
End point description: Cohort 3b included subjects with colorectal cancer treated with escalating doses of vemurafenib and cetuximab. The escalating doses were as follows: Dose Level 1: 720 milligrams (mg) of vemurafenib orally twice daily starting on Day 2 of Cycle 1 and 300 milligrams per square meter (mg/m <sup>2</sup> ) loading dose of cetuximab by infusion and then 200 mg/m <sup>2</sup> weekly; Dose Level 2: 720 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m <sup>2</sup> loading dose of cetuximab and then 250 mg/m <sup>2</sup> weekly; Dose Level 3: 960 mg of vemurafenib twice daily starting on Day 2 of Cycle 1 and 400 mg/m <sup>2</sup> loading dose of cetuximab and then 250 mg/m <sup>2</sup> weekly. Reported here are type and number of dose limited toxicities observed. The safety population included all subjects who received at least one dose of study medication.	
End point type	Secondary
End point timeframe: Up to 28 days	

End point values	Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[15]</sup>	0 <sup>[16]</sup>	0 <sup>[17]</sup>	14
Units: dose-limiting toxicities				
Grade 3 amylase increased				1
Grade 4 lipase increased				1

Notes:

[15] - Endpoint only applies to combination therapy in cohort 3b.

[16] - Endpoint only applies to combination therapy in cohort 3b.

[17] - Endpoint only applies to combination therapy in cohort 3b.

End point values	Cohort 4: Cholangiocarcinoma - vemurafenib	Cohort 6: Multiple Myeloma - vemurafenib	Cohort 7a: ECD/LCH - vemurafenib	Cohort 7b: Anaplastic Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[18]</sup>	0 <sup>[19]</sup>	0 <sup>[20]</sup>	0 <sup>[21]</sup>
Units: dose-limiting toxicities				
Grade 3 amylase increased				
Grade 4 lipase increased				

Notes:

[18] - Endpoint only applies to combination therapy in cohort 3b.

[19] - Endpoint only applies to combination therapy in cohort 3b.

[20] - Endpoint only applies to combination therapy in cohort 3b.

[21] - Endpoint only applies to combination therapy in cohort 3b.

End point values	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 <sup>[22]</sup>	0 <sup>[23]</sup>	0 <sup>[24]</sup>	
Units: dose-limiting toxicities				
Grade 3 amylase increased				
Grade 4 lipase increased				

Notes:

[22] - Endpoint only applies to combination therapy in cohort 3b.

[23] - Endpoint only applies to combination therapy in cohort 3b.

[24] - Endpoint only applies to combination therapy in cohort 3b.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Safety: Percentage of Subjects with Adverse Event

End point title	Safety: Percentage of Subjects with Adverse Event
-----------------	---

End point description:

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. The safety population included all subjects who received at least one dose of study medication.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to approximately 3 years

End point values	Cohort 1: Non- Small Cell Lung Cancer (NSCLC) - vemurafenib	Cohort 2: Ovarian Cancer - vemurafenib	Cohort 3a: Colorectal Cancer - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	62	4	10	27
Units: percentage of subjects				
number (not applicable)	100	100	100	100

End point values	Cohort 4: Cholangiocarci	Cohort 6: Multiple	Cohort 7a: ECD/LCH -	Cohort 7b: Anaplastic
------------------	-----------------------------	-----------------------	-------------------------	--------------------------



	noma - vemurafenib	Myeloma - vemurafenib	vemurafenib	Thyroid Cancer - vemurafenib
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	9	26	12
Units: percentage of subjects				
number (not applicable)	100	100	100	91.7

<b>End point values</b>	Cohort 7c: Advanced Stage Astrocytoma - vemurafenib	Cohort 7d: Early Stage Astrocytoma - vemurafenib	Other BRAF V600-positive Tumors - vemurafenib	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	12	9	28	
Units: percentage of subjects				
number (not applicable)	100	100	100	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From baseline up to approximately 3 years

Adverse event reporting additional description:

The safety population included all subjects who received at least one dose of study medication.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

### Reporting groups

Reporting group title	Pooled arm - vemurafenib
-----------------------	--------------------------

Reporting group description:

Subjects with a variety of cancer types, who were treated with vemurafenib monotherapy, were combined into this arm.

Reporting group title	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab
-----------------------	--

Reporting group description:

Subjects with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.

Serious adverse events	Pooled arm - vemurafenib	Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab	
Total subjects affected by serious adverse events			
subjects affected / exposed	91 / 181 (50.28%)	11 / 27 (40.74%)	
number of deaths (all causes)	87	25	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Squamous cell carcinoma of skin			
subjects affected / exposed	25 / 181 (13.81%)	3 / 27 (11.11%)	
occurrences causally related to treatment / all	38 / 39	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Keratoacanthoma			
subjects affected / exposed	18 / 181 (9.94%)	2 / 27 (7.41%)	
occurrences causally related to treatment / all	28 / 28	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	7 / 181 (3.87%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	11 / 13	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Squamous cell carcinoma			
subjects affected / exposed	1 / 181 (0.55%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bowen's disease			
subjects affected / exposed	4 / 181 (2.21%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	4 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic myelomonocytic leukaemia			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraganglion neoplasm			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of lung			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Jugular vein thrombosis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration			

site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 181 (0.00%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	2 / 181 (1.10%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	2 / 181 (1.10%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthermia			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Prostatitis			
subjects affected / exposed	2 / 181 (1.10%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Benign prostatic hyperplasia			

subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uterine haemorrhage			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal haemorrhage			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pulmonary thrombosis			
subjects affected / exposed	0 / 181 (0.00%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	3 / 181 (1.66%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	3 / 181 (1.66%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Respiratory failure			
subjects affected / exposed	2 / 181 (1.10%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Laryngeal dyspnoea			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			

subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Delirium			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Depression			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 181 (0.00%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Body temperature increased			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 181 (0.00%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture			

subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Limb injury			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	2 / 181 (1.10%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	2 / 181 (1.10%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dressler's syndrome			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			

Aphasia	subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Brain oedema	subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
	occurrences causally related to treatment / all	1 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhagic stroke	subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Partial seizures	subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral motor neuropathy	subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Posterior reversible encephalopathy syndrome	subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure	subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack	subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
	occurrences causally related to treatment / all	0 / 1	0 / 0	
	deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders				



Pseudolymphoma			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Splenic infarction			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Iridocyclitis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 181 (0.55%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	0 / 181 (0.00%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal perforation			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric ulcer			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Stomatitis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 181 (0.00%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bile duct obstruction			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-induced liver injury			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Acute febrile neutrophilic dermatosis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin lesion			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			

subjects affected / exposed	4 / 181 (2.21%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	4 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder dilatation			
subjects affected / exposed	0 / 181 (0.00%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive uropathy			
subjects affected / exposed	0 / 181 (0.00%)	1 / 27 (3.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Sepsis			
subjects affected / exposed	6 / 181 (3.31%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	2 / 6	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonia			
subjects affected / exposed	5 / 181 (2.76%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	4 / 181 (2.21%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Bronchitis			
subjects affected / exposed	3 / 181 (1.66%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	2 / 181 (1.10%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal abscess			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Furuncle			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Soft tissue infection			

subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Diabetes mellitus			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Glucose tolerance impaired			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	1 / 181 (0.55%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	3 / 181 (1.66%)	0 / 27 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	<b>Pooled arm - vemurafenib</b>	<b>Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab</b>	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	177 / 181 (97.79%)	26 / 27 (96.30%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acrochordon			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	3	
Melanocytic naevus			
subjects affected / exposed	41 / 181 (22.65%)	4 / 27 (14.81%)	
occurrences (all)	67	4	
Seborrhoeic keratosis			
subjects affected / exposed	36 / 181 (19.89%)	3 / 27 (11.11%)	
occurrences (all)	49	3	
Skin papilloma			
subjects affected / exposed	50 / 181 (27.62%)	7 / 27 (25.93%)	
occurrences (all)	86	8	
Papilloma			
subjects affected / exposed	17 / 181 (9.39%)	0 / 27 (0.00%)	
occurrences (all)	21	0	
Vascular disorders			
Hypertension			
subjects affected / exposed	28 / 181 (15.47%)	3 / 27 (11.11%)	
occurrences (all)	38	3	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	39 / 181 (21.55%)	10 / 27 (37.04%)	
occurrences (all)	44	13	
Chest pain			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	2	
Chills			
subjects affected / exposed	10 / 181 (5.52%)	2 / 27 (7.41%)	
occurrences (all)	10	2	
Fatigue			

subjects affected / exposed occurrences (all)	60 / 181 (33.15%) 68	6 / 27 (22.22%) 8	
Oedema peripheral subjects affected / exposed occurrences (all)	21 / 181 (11.60%) 25	4 / 27 (14.81%) 4	
Pyrexia subjects affected / exposed occurrences (all)	26 / 181 (14.36%) 30	5 / 27 (18.52%) 11	
Cyst subjects affected / exposed occurrences (all)	21 / 181 (11.60%) 26	0 / 27 (0.00%) 0	
Xerosis subjects affected / exposed occurrences (all)	16 / 181 (8.84%) 18	0 / 27 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	31 / 181 (17.13%) 42	2 / 27 (7.41%) 4	
Dysphonia subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	2 / 27 (7.41%) 2	
Dyspnoea subjects affected / exposed occurrences (all)	22 / 181 (12.15%) 27	5 / 27 (18.52%) 7	
Nasal congestion subjects affected / exposed occurrences (all)	10 / 181 (5.52%) 11	0 / 27 (0.00%) 0	
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	14 / 181 (7.73%) 14	2 / 27 (7.41%) 2	
Depression subjects affected / exposed occurrences (all)	10 / 181 (5.52%) 10	3 / 27 (11.11%) 5	
Insomnia			

subjects affected / exposed occurrences (all)	18 / 181 (9.94%) 19	0 / 27 (0.00%) 0	
Investigations			
Amylase increased subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	6 / 27 (22.22%) 6	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	15 / 181 (8.29%) 15	2 / 27 (7.41%) 2	
Blood bilirubin increased subjects affected / exposed occurrences (all)	10 / 181 (5.52%) 14	3 / 27 (11.11%) 3	
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	37 / 181 (20.44%) 52	4 / 27 (14.81%) 4	
Lymphocyte count decreased subjects affected / exposed occurrences (all)	0 / 181 (0.00%) 0	3 / 27 (11.11%) 6	
Lipase increased subjects affected / exposed occurrences (all)	10 / 181 (5.52%) 21	9 / 27 (33.33%) 10	
Weight decreased subjects affected / exposed occurrences (all)	20 / 181 (11.05%) 20	6 / 27 (22.22%) 6	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	15 / 181 (8.29%) 17	0 / 27 (0.00%) 0	
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	11 / 181 (6.08%) 12	0 / 27 (0.00%) 0	
Blood creatinine increased subjects affected / exposed occurrences (all)	19 / 181 (10.50%) 26	0 / 27 (0.00%) 0	
Injury, poisoning and procedural complications			



Fall			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	3	
Sunburn			
subjects affected / exposed	22 / 181 (12.15%)	4 / 27 (14.81%)	
occurrences (all)	27	4	
Nervous system disorders			
Headache			
subjects affected / exposed	26 / 181 (14.36%)	4 / 27 (14.81%)	
occurrences (all)	30	5	
Dysgeusia			
subjects affected / exposed	24 / 181 (13.26%)	0 / 27 (0.00%)	
occurrences (all)	25	0	
Peripheral sensory neuropathy			
subjects affected / exposed	27 / 181 (14.92%)	0 / 27 (0.00%)	
occurrences (all)	27	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	30 / 181 (16.57%)	3 / 27 (11.11%)	
occurrences (all)	40	3	
Eye disorders			
Dry eye			
subjects affected / exposed	11 / 181 (6.08%)	0 / 27 (0.00%)	
occurrences (all)	11	0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	12 / 181 (6.63%)	12 / 27 (44.44%)	
occurrences (all)	13	18	
Abdominal pain upper			
subjects affected / exposed	0 / 181 (0.00%)	4 / 27 (14.81%)	
occurrences (all)	0	4	
Constipation			
subjects affected / exposed	26 / 181 (14.36%)	5 / 27 (18.52%)	
occurrences (all)	30	6	
Diarrhoea			
subjects affected / exposed	49 / 181 (27.07%)	13 / 27 (48.15%)	
occurrences (all)	67	30	

Dyspepsia			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	3	
Flatulence			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	5	
Nausea			
subjects affected / exposed	54 / 181 (29.83%)	9 / 27 (33.33%)	
occurrences (all)	80	13	
Rectal haemorrhage			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	3	
Stomatitis			
subjects affected / exposed	19 / 181 (10.50%)	4 / 27 (14.81%)	
occurrences (all)	20	5	
Vomiting			
subjects affected / exposed	41 / 181 (22.65%)	8 / 27 (29.63%)	
occurrences (all)	55	10	
Dry mouth			
subjects affected / exposed	12 / 181 (6.63%)	0 / 27 (0.00%)	
occurrences (all)	16	0	
Dysphagia			
subjects affected / exposed	14 / 181 (7.73%)	0 / 27 (0.00%)	
occurrences (all)	16	0	
Hepatobiliary disorders			
Hyperbilirubinaemia			
subjects affected / exposed	11 / 181 (6.08%)	0 / 27 (0.00%)	
occurrences (all)	14	0	
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	28 / 181 (15.47%)	4 / 27 (14.81%)	
occurrences (all)	51	4	
Alopecia			
subjects affected / exposed	57 / 181 (31.49%)	2 / 27 (7.41%)	
occurrences (all)	58	2	
Dermatitis acneiform			

subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)
occurrences (all)	0	2
Dermatitis bullous		
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)
occurrences (all)	0	2
Dry skin		
subjects affected / exposed	39 / 181 (21.55%)	2 / 27 (7.41%)
occurrences (all)	42	2
Hyperkeratosis		
subjects affected / exposed	58 / 181 (32.04%)	4 / 27 (14.81%)
occurrences (all)	102	9
Erythema		
subjects affected / exposed	24 / 181 (13.26%)	7 / 27 (25.93%)
occurrences (all)	34	11
Pruritus		
subjects affected / exposed	42 / 181 (23.20%)	5 / 27 (18.52%)
occurrences (all)	47	5
Photosensitivity reaction		
subjects affected / exposed	39 / 181 (21.55%)	5 / 27 (18.52%)
occurrences (all)	44	5
Rash		
subjects affected / exposed	44 / 181 (24.31%)	10 / 27 (37.04%)
occurrences (all)	60	16
Rash generalised		
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)
occurrences (all)	0	2
Rash maculo-papular		
subjects affected / exposed	42 / 181 (23.20%)	3 / 27 (11.11%)
occurrences (all)	59	5
Skin fissures		
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)
occurrences (all)	0	2
Toxic skin eruption		
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)
occurrences (all)	0	2
Dermal cyst		

subjects affected / exposed	18 / 181 (9.94%)	0 / 27 (0.00%)	
occurrences (all)	24	0	
Dermatitis			
subjects affected / exposed	10 / 181 (5.52%)	0 / 27 (0.00%)	
occurrences (all)	10	0	
Keratosis pilaris			
subjects affected / exposed	33 / 181 (18.23%)	0 / 27 (0.00%)	
occurrences (all)	33	0	
Milia			
subjects affected / exposed	16 / 181 (8.84%)	0 / 27 (0.00%)	
occurrences (all)	18	0	
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	48 / 181 (26.52%)	0 / 27 (0.00%)	
occurrences (all)	57	0	
Papule			
subjects affected / exposed	13 / 181 (7.18%)	0 / 27 (0.00%)	
occurrences (all)	18	0	
Rash papular			
subjects affected / exposed	21 / 181 (11.60%)	0 / 27 (0.00%)	
occurrences (all)	26	0	
Skin lesion			
subjects affected / exposed	11 / 181 (6.08%)	0 / 27 (0.00%)	
occurrences (all)	18	0	
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	3	
Micturition urgency			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	2	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	79 / 181 (43.65%)	14 / 27 (51.85%)	
occurrences (all)	123	21	
Back pain			

subjects affected / exposed	18 / 181 (9.94%)	4 / 27 (14.81%)	
occurrences (all)	21	4	
Muscle spasms			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	3	
Myalgia			
subjects affected / exposed	18 / 181 (9.94%)	3 / 27 (11.11%)	
occurrences (all)	23	4	
Pain in extremity			
subjects affected / exposed	13 / 181 (7.18%)	2 / 27 (7.41%)	
occurrences (all)	14	5	
Musculoskeletal pain			
subjects affected / exposed	14 / 181 (7.73%)	0 / 27 (0.00%)	
occurrences (all)	15	0	
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	0 / 181 (0.00%)	3 / 27 (11.11%)	
occurrences (all)	0	3	
Folliculitis			
subjects affected / exposed	18 / 181 (9.94%)	3 / 27 (11.11%)	
occurrences (all)	24	3	
Oral candidiasis			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	2	
Rash pustular			
subjects affected / exposed	0 / 181 (0.00%)	3 / 27 (11.11%)	
occurrences (all)	0	3	
Skin infection			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	2	
Urinary tract infection			
subjects affected / exposed	0 / 181 (0.00%)	3 / 27 (11.11%)	
occurrences (all)	0	6	
Metabolism and nutrition disorders			
Decreased appetite			

subjects affected / exposed	50 / 181 (27.62%)	10 / 27 (37.04%)	
occurrences (all)	56	15	
Dehydration			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	2	
Hyperglycaemia			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	3	
Hypoalbuminaemia			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	2	
Hypokalaemia			
subjects affected / exposed	18 / 181 (9.94%)	5 / 27 (18.52%)	
occurrences (all)	20	7	
Hyponatraemia			
subjects affected / exposed	0 / 181 (0.00%)	2 / 27 (7.41%)	
occurrences (all)	0	4	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
09 August 2012	Cohort 3 was split into two – the pre-existing Cohort 3a - vemurafenib only, and a new Cohort 3b - combination therapy with vemurafenib and cetuximab. The protocol was amended to include rationale for vemurafenib and cetuximab treatment in this cohort.
18 March 2014	Additional subjects (up to 70 subjects in total) were allowed to be recruited into a study cohort if a promising response rate was demonstrated in Stage II of that cohort. The exploratory objectives for the study were revised.
16 January 2015	The secondary objectives were changed to include the evaluation of tumor assessment scans by an independent review committee (IRC) for Cohort 1 (NSCLC) and other cohorts that demonstrate clinically meaningful efficacy per investigator assessment. The presence of BRAF V600 mutations could be retrospectively confirmed. Inclusion criteria for all subjects were changed to include male or female $\geq 16$ years of age. Inclusion criteria for solid tumors and multiple myeloma were changed so that in order for the subject to be eligible, they must be able to provide a tumor sample (preferably tissue; alternatively DNA) for retrospective confirmation of the BRAF mutation by a central laboratory. IRC assessment of response rates was added a secondary efficacy endpoint focusing on Week 8, Week 16 and BOR for Cohort 1 (NSCLC) and other cohorts that demonstrate clinically meaningful efficacy per investigator assessment.
24 March 2016	Prior to the closure of the trial or should the study be closed due to Sponsor decision, it was added that the Sponsor may offer subjects who have completed the protocol-mandated minimum 12-month safety follow-up and who continue to benefit from vemurafenib therapy, the opportunity to receive continued vemurafenib via enrollment in the GO28399 extension trial. The interim analysis was changed to add efficacy analysis at 9 months for expanded cohorts. In case a cohort/indication is expanded up to 70 subjects, the primary analysis for efficacy will occur once all subjects have been followed up for 9 months after last subject had been enrolled in that cohort, or the subject develops progressive disease, withdraws consent, or is lost to follow-up, whichever occurred first.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported